Lapaquistat acetate: Development of a squalene synthase inhibitor for the treatment of hypercholesterolemia

Circulation

Volumn 123, Issue 18, 2011, Pages 1974-1985

  Stein, Evan A ^a   Bays, Harold ^b   O'Brien, Dennis ^c   Pedicano, Jim ^c   Piper, Edward ^c   Spezzi, Andrea ^c  

^a Metabolic and Atherosclerosis Research Center   (United States)

^b LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^c TAKEDA PHARMACEUTICALS   (United States)

Author keywords

C reactive protein; cholesterol LDL; clinical trials; drug therapy; lipoproteins LDL

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; BILIRUBIN; C REACTIVE PROTEIN; EZETIMIBE; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAPAQUISTAT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; SQUALENE SYNTHASE;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BACKACHE; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR RISK; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ENZYME INHIBITION; ERYTHEMA; FAMILIAL HYPERCHOLESTEROLEMIA; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; METABOLIC PARAMETERS; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; RASH; RHINOPHARYNGITIS; SCLERA DISEASE; SIDE EFFECT; SKIN ABRASION; UPPER RESPIRATORY TRACT INFECTION; URINE COLOR; VOMITING; WEAKNESS;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIVER DISEASES; MALE; MIDDLE AGED; OXAZEPINES; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79955762929     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.975284     Document Type: Article

References (23)

1. Marcoff L, Thompson PD. The role of coenzyme Q10 in statinassociated myopathy: a systematic review. J Am Coll Cardiol. 2007; 49:2231-2237. (Pubitemid 46856819)
2. Stein EA. Other therapies for reducing low-density lipoprotein cholesterol: medications in development. Endocrinol Metab Clin N Am. 2009;38: 99-119.
3. Lipid Research Clinics. Manual of Laboratory Operations: Lipid and Lipoprotein Analysis (Revised). Washington, DC: US Government Printing Office; 1982. US Department of Health and Human Services publication No. (NIH) 75-678.
4. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
5. Reuben A. Hy's law. Hepatology. 2004;39:574-578.
6. Amano Y, Nishimoto T, Tozawa R, Ishikawa E, Imura Y, Sugiyama Y. Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia. Eur J Pharmacol. 2003; 466:155-161. (Pubitemid 36385101)
7. Temple R. Hepatotoxicity through the years: impact on the FDA. Paper presented at: Drug-Induced Liver Injury: A National and Global Problem Conference; February 12-13, 2001;; Chantilly, VA. www.fda.gov/Drugs/ ScienceResearch/ResearchAreas/ucm091365.htm#temple. Accessed October 30, 2009.
8. Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349: 474-495.
9. Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf. 2006;15:241-243.
10. US Food and Drug Administration Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. July 2009. www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM174090.pdf. Accessed October 30, 2009.
11. Watkins PB, Seligman PJ, Pears JS, Avigan MI, Senior JR. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology. 2008;48:1680-1689.
12. Lipitor (atorvastatin calcium tablets) [US prescribing information[. Morris Plains, NJ: Parke-Davis Division of Warner-Lambert Co; January 1997.
13. Illingworth DR, Crouse JR 3rd, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef AF, Paragh G, Ma PT, Liu M, Melino MR, O'Grady L, Mercuri M, Mitchel YB; Simvastatin Atorvastatin HDL Study Group. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin. 2001;17:43-50. (Pubitemid 32594972)
14. Bays H. Statin safety: an overview and assessment of the data-2005. Am J Cardiol. 2006;97:6C-26C.
15. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol. 1997;80:106-107.
16. Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, Rader DJ. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2008;5:497-505.
17. Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fritz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med. 2002;162(14):1568-1576. (Pubitemid 34765005)
18. Despres JP, Lemieux I, Pascot A, Alméras N, Dumont M, Nadeau A, Bergeron J, Prud'homme D. Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2003; 23:702-703. (Pubitemid 36438087)
19. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP. Effect of ezetimibe coadmin-istered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial Circulation. 2003; 107(19):2409-2415. (Pubitemid 36605221)
20. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38. (Pubitemid 40075678)
21. Bays HE, Stein EA, Shah AK, Maccubin DL, Mitchel YB, Mercuri M. Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. Am J Cardiol. 2002;90:942-946. (Pubitemid 35232616)
22. Pearson TA, Ballantyne CM, Veltri E, Shah A, Bird S, Lin J, Rosenberg E, Tershakovec AM. Pooled analysis of effects on C-reactive protein and LDL cholesterol in placebo controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol. 2009;103:369-374.
23. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J, Hurley DP, Langendorfer A, Nash DT, Pool JL, Schnaper H. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results, I: efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991;151:43-49.